What is the half-life of Follistatin 344?

Follistatin 344 has a half-life of Not well characterized; estimated several hours for circulating forms, which is why it's typically administered Once daily for 10-30 days for optimal therapeutic effect.

How do I reconstitute Follistatin 344?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Muscle Growth

Preclinical

Follistatin 344

Also known as: FS-344, FST-344, Follistatin

Overview

Key Facts

Primary Goal: A naturally occurring glycoprotein that acts as a potent inhibitor of myostatin and other TGF-beta superfamily members such as activin

A naturally occurring glycoprotein that acts as a potent inhibitor of myostatin and other TGF-beta superfamily members such as activin. The 344 isoform is the full-length precursor that is processed into shorter circulating forms. By neutralizing myostatin, Follistatin 344 removes the endogenous brake on skeletal muscle growth, enabling significant hypertrophy beyond normal physiological limits. Half-Life Not well characterized; estimated several hours for circulating forms Typical Dose 100–300 mcg Frequency Once daily for 10-30 days Cycle Length 10-30 days (short cycles due to limited safety data)

Dosing Information

Half-Life

Not well characterized; estimated several hours for circulating forms

Typical Dose

100–300 mcg

Frequency

Once daily for 10-30 days

Cycle Length

10-30 days (short cycles due to limited safety data)

Administration Routes:

subcutaneousintramuscular

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

Animal studies have demonstrated dramatic increases in muscle mass (up to 100-200% in myostatin-knockout models). A gene therapy trial using AAV-delivered follistatin (NCT01519349) showed increased distance walked in Becker muscular dystrophy patients. The injectable peptide form has limited human clinical data but extensive preclinical evidence supporting its myostatin-inhibiting properties.